amr industry alliance

uniting to act on antimicrobial resistance

The AMR Industry Alliance is one of the largest private sector coalitions set up to provide sustainable solutions to curb antimicrobial resistance, with over 100 biotech, diagnostics, generics and research-based pharmaceutical companies and associations joining forces.

We drive and measure the life-sciences industry progress to curb antimicrobial resistance in four different areas:

Invest in R&D to meet public health needs with new innovative diagnostics & treatments

Improve access to high-quality antibiotics and ensuring that new ones are available to all

Work to reduce the development of antimicrobial resistance

Support measures to reduce environmental impact from production of antibiotics

shared goals

We are uniting efforts to reduce the development of antimicrobial resistance, invest in R&D to meet public health needs and improve access to antibiotics, vaccines and diagnostics.

find out more

progress report

Despite the ongoing challenges presented by the pandemic, the AMR Industry Alliance’s 2021 Progress Report captures efforts made by the life sciences industry to fight AMR across several domains: research and science, access, appropriate use, and manufacturing. The third iteration of this biannual report captures progress made by Alliance members between July 2019 and March 2021. Find out more below.

find out more

in action

Our case studies provide snap-shots from across the life-sciences industry, share information on the tangible steps we are taking to invest in new research to develop new antibiotics and vaccines, prevent infection, and improve appropriate use of antibiotics.

find out more

latest news

23/10/2025

AMR Industry Alliance Releases “Principles for Pooled Procurement of AMR Products” to Strengthen Access and Market Stability in Low- and Lower-Middle-Income Countries

The AMR Industry Alliance is proud to announce the publication of its new guidance document: “Principles for Pooled Procurement of AMR Products.” This document is intended to support purchasers in...

AMR Industry Alliance Updates Responsible Manufacturing Standard, Further Aligning with WHO Guidance

Geneva, Switzerland, 13 May 2025 — The AMR Industry Alliance today announced it has updated its Antibiotic Manufacturing Standard, further aligning the framework with the World Health Orga...

NHS launches ‘subscription’ scheme for antibiotics with pharma sector

Drugmakers will receive flat fees for new medicines in push to avoid encouraging overuse The NHS will agree subscription-style deals with drugmakers for antibiotics, as the UK seeks to enco...

amr in numbers

AMR Impact

Life-sciences at the forefront of the battle against AMR

Development of National Action Plans

R&D

Biotechs

Diagnostics

from the blog

Posted on 18/11/2020
By Dr Ron Daniels

Antimicrobial Resistance and the Burden of Sepsis

Sepsis is a devastating condition resulting from a dysregulated immune system response to infection, which can lead to organ failure and death. Each year, sepsis affects close to 50 million people globally, of whom more than 40% are children under age 5 particularly in low- and middle-income countri...

from twitter

@amralliance

No feed found with the ID 1. Go to the All Feeds page and select an ID from an existing feed.